Kornimate/medical-research-clean huggingface dataset:
4d cone beam ct reconstruction for radiotherapy via motion vector optimization

Conditions: Lung Cancer

Summary: to validate a new 4d cone beam ct (4dcbct) reconstruction algorithm that was developed in our research group recently in terms of its geometry and intensity accuracy through real patient studies. dose calculation found out in this study will not be used on the subject

before patient studies, we will have conducted experimental studies on a lung phantom. the purpose of this step is to comprehensively evaluate the system performance and gain confidence prior to its applications to real patient cases. we will operate the phantom to simulate motion patterns with different motion amplitude/frequency. 4dcbct images will be reconstructed using our method and the conventional fdk algorithm. the validation will focus on two aspects: hu value accuracy and anatomy location accuracy. imaging dose in these scans will be also measured in phantom studies to make sure the radiation dose level is acceptable for patient studies. adiation dose level is acceptable for patient studies. after testing the reconstruction algorithm on phantoms, we will move on to real patient cases. we will conduct patient studies on lung cancer patients treated under image guided radiation therapy (igrt) at department of radiation oncology, ut southwestern medical center. cbct projection data will be collected (4 gantry rotations, each within 1 minute) in only one treatment fraction. 4dcbct images will be reconstructed from the current standard fdk algorithm using all the projection data, and from our system using data only in the first gantry rotation. patient 4dct image will also be used, which have been acquired during treatment planning stage per standard treatment protocol at utsw. the image quality of our 4dcbct will be assessed in two aspects: 1) geometry accuracy, by comparing selected anatomical landmark locations with those in 4dcbct reconstructed by the fdk algorithm. 2) hu accuracy, by comparing hu values in selected regions of interest (rois) with those in 4dct. the 4dct images will be extracted from radiation therapy information system mosaiq. the cbct projection data will be exported from a computer that controls the image acquisition system

Eligibility criteria:
inclusion criteria: 1. patients that have been diagnosed with lung cancer, and are treated at department of radiation oncology, utsw. 2. patients are greater than 18 years of age. 3. patients understand a written informed consent document and are willing to sign the consent form. exclusion criteria: 1. women who are pregnant or trying to get pregnant 2. children (under age of 18)
tf-cbt for adjudicated youth in residential treatment

Conditions: PTSD

Summary: adjudicated youth often have traumatic stress responses but rarely receive treatment for these problems. this study is a randomized controlled trial to evaluate two alternative implementation strategies for providing an evidence-based trauma treatment, trauma-focused cognitive behavioral therapy (tf-cbt), to therapist who treat adjudicated youth in 18 residential treatment facilities (rtf) in new hampshire, vermont, and connecticut: 1) web-based tf-cbt implementation strategy ("w"), consisting on only web-based training and consultation; versus 2) w plus live tf-cbt implementation strategy, consisting of w plus face-to face training and phone consultation with tf-cbt experts ("w+l").

therapists in each of 18 participating rtfprograms that serve adjudicated youth are randomized to receive either: 1. w tf-cbt implementation strategy, provided via the free distance learning resources tf-cbtweb, (www.musc/edu/tfcbt) and tf-cbtconsult (www.musc.edu/tfcbtconsult); or 2. w+l implementation strategy, provided through w + 2 day tf-cbt training plus one year of twice monthly tf-cbt consultation calls with a tf-cbt expert trainer. all rtf staff receive one day training in trauma-informed care. all therapists in both conditions receive training in screening youth for trauma exposure and symptoms. data are collected regarding primary outcomes of: 1) number of youth therapists in each condition screen for trauma symptoms, 2) number of youth consent to tf-cbt treatment; 3) number of youth complete tf-cbt, 4) tf-cbt fidelity during treatment. secondary outcomes include 1)changes in therapist knowledge and satisfaction regarding tf-cbt treatment and 2) youth outcomes including ptsd symptoms, depression and satisfaction with treatment.

Eligibility criteria:
inclusion criteria: consenting mental health therapists in participating residential treatment facilities (rtf)in new hampshire, vermont and connecticut; and the adjudicated youth ages 12-17 years old who are residents in these rtf programs being treated by the participating therapists who 1) are screened positive for having at least one past trauma experience with ucla ptsd reaction index score of \>22; 2) assent with legal guardian consent to participate in the project; and 3) are anticipated to remain in the rtf program at least 3 months (long enough to receive tf-cbt treatment). - exclusion criteria: guardian or youth refuses;youth does not endorse trauma exposure or symptoms; youth is being discharged too soon to participate; therapist may use clinical judgment to exclude youth from study based on clinical presentation. -

Keywords: implementation; tf-cbt; adjudicated youth; rtf; trauma
cut-off values of muscle thickness ratio for sarcopenia

Conditions: Sarcopenia

Summary: the loss of muscle mass is one of the major diagnostic criteria for sarcopenia. many methods are also used for the definition of sarcopenia. however there is no information about cut-off values in this respect in the literature. therefore, the aim of this study is to determine the cut-off values of this ratio for confirming the diagnosis of sarcopenia.

decreases in total skeletal muscle mass are accepted to be necessary for confirming the diagnosis of sarcopenia. many methods are also used for the definition of sarcopenia. however, ultrasound measurements has a high sensitivity and specify for confirming the diagnosis of sarcopenia. however there is no information about cut-off values in this respect in the literature. therefore, the aim of this study is to determine the cut-off values of this ratio for confirming the diagnosis of sarcopenia.

Eligibility criteria:
inclusion criteria: * to be a volunteer to participate * to be an aged 18-90 years old. exclusion criteria: * walking with assist device * having a visual deficits * having an undergone orthopedic surgery * having a cardiac pacemaker * having a hypothyroidism, diabetes mellitus, renal/hepatic failure

Keywords: older people muscle ultrasound
effects of newly-created individualized upper airway muscle functional training on patients with osa

Conditions: Obstructive Sleep Apnea; Muscle Disorder

Summary: objectives: to observe the effect of newly-created individualized upper airway muscle functional training on the condition and intraday symptoms of osa patients; to study the effect of this training method on the excitability of the genioglossus muscle cortex; to analyze the factors affecting the efficacy of upper airway training in the treatment of osa and screening suitable population for upper airway training: design: a randomized double-blind controlled trial. sas 9.3 statistical software (sas institute, cary, north carolina, usa) was used to generate a random number table, and the selected patients were randomly divided into experimental group 1, experimental group 2, and control group according to the ratio of 1:1:1 with 100 cases each. unit: shenyang, china participants: consecutive specific osa patients, who are potential candidates for the treatment of upper airway training (n=300), will be recruited from a sleep center or respirologists, psychiatrists, otolaryngologists and dentists practicing with broad inclusion criteria (age: 20-75 years, ahi:15-50/h; bmi\<40 kg/m2). interventions: the three groups of subjects completed 7-day functional training and control training of upper airway muscles in different modes, respectively completed polysomnography, neck circumference, berlin questionnaire and epworth sleepiness scale before and after training, the genioglossus myoelectric activity was measured after transcranial magnetic stimulation and the excitability of the genioglossus cortex motor center was used to determine the efficacy of different training. after regression analysis, the factors affecting the efficacy of upper airway muscle group training were analyzed to screen the osa patient population suitable for upper airway muscle group training.


Eligibility criteria:
inclusion criteria: * recent diagnosis of osa (ahi\>15 events/h) announced by a sleep recording * mean oxygen saturation \>90% * must be able to complete the training exclusion criteria: * inability to tolerate overnight polysomnography in sleep lab * \>50% of observed sleep apneas being central * other sleep disorders such as insomnia, narcolepsy, chronic sleep deficiency, periodic limb movement disorder or restless legs syndrome
effect of waterpipe smoking on periodontal health

Conditions: Waterpipe Smoking; Periodontal Diseases

Summary: the main objective of the study is to assess the effect of waterpipe smoking on periodontal health, which will be done using a well constructed validated questionnaire. then a full periodontal examination and x-ray evaluation will be done for all of the participants.

the primary outcome of the study is to assess the effect of waterpipe smoking on periodontal health, it will be assessed by questions about smoking habits, including smoking mode as well as duration (heads smoked per day) and extent of use (age of initiation and number of sessions per week) of waterpipe smoking. a full periodontal examination using unc-15 periodontal probe will be done for all of the participants measuring the cal, probing depth (pd), plaque index (pi), bleeding on probing (bop) and gingival recession depth (gd). in subjects where attachment loss will be clinically detected, radiographic examination will be performed by digital periapical radiograph to detect the amount of bone loss, then staging will be done according to the new classification by the aid of radiographic examination.

Eligibility criteria:
inclusion criteria: 1. patients whose age is between 18-60 years old. 2. patient consulting in the outpatient clinic. 3. provide informed consent. exclusion criteria: 1. individuals with chronic systemic diseases such as diabetes, endocrine and hematological pathologies. 2. patients having problem in opening their mouth or undergoing intermaxillary fixation where oral examination will not be possible. 3. pregnant women. 4. patients diagnosed with psychiatric problems or intoxicated with alcohol or drugs. 5. patients with orthodontic appliances.
liver transplantation in patients with incidental hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-center experience

Conditions: Adult Combined Hepatocellular-Cholangiocarcinoma

Summary: liver transplantation has become an important treatment in hepatocellular cancer (hcc). while the generally determined malign indication in the world is hcc, some centers perform liver transplantation in both cholangiocarcinoma and mixed type hepatocellular-cholangiocarcinoma diseases and investigate the differences in recurrence and survival outcomes compared to hcc. although liver transplantation for intrahepatic cholangiocarcinomas of small diameter \<2cm is a popular topic of discussion around the world, a common consensus has not been established.

combined hepatocellular and cholangiocarcinoma (chc) with an incidence rate from 0.4% to 14.2% in different regions, characterized by hepatocellular and biliary epithelial differentiation within the same tumor, is an unique type of primary hepatic carcinoma that is distinct from hepatocellular carcinoma (hcc) and intrahepatic cholangiocarcinoma (icc). combined hepatocellular and cholangiocarcinoma is having attention clinically and pathologically, because of its unique biology, histopathology, and clinical behavior, besides the difficulties in diagnosis and being rare (comprising 1-5% of primary liver cancer). the investigators aimed to present our experience with patients misdiagnosed before lt and found to have incidentally icc or chc on explant and compare with hcc, and to identify the demographic, clinical, pathological and etiological risk factors of recurrence and prognostic factors of survival. liver transplantation has been tried as an effective treatment in mixed-type hepatocellular-cholangiocarcinomas and intrahepatic cholangiocarcinomas, but survival and recurrence-free outcomes have not been achieved as well as hcc. in addition, survival rates reported in different centers also vary. prognostic factors that may affect disease recurrence and survival include etiology, body mass index, afp, cea, ca 19-9, ck7, ck19, cd34, cd56, cd117, cd133, hsa, arginase, heppar, amacyr, glypican 3, synaptophysin, ck20, cdx2, p53, ki67, milan criteria, tumor size, tumor number, maximum tumor diameter, total tumor diameter, tumor grade, multicentricity, microvascular invasion, macrovascular invasion, vascular invasion, tumor tnm stage. i̇nvestigating whether there is a difference between mixed type hepatocellular-cholangiocarcinomas compared to hcc in terms of survival, recurrence and other prognostic markers mentioned above would be important for mixed type tumor relations with liver transplantation.

Eligibility criteria:
inclusion criteria: 1. explant pathology being combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma 2. having a liver transplant 3. being over 18 years old exclusion criteria: 1. explant pathology being hepatocellular carcinoma 2. being under the age of 18
phase ii bgg492 capsule extension for partial epilepsy

Conditions: Partial Onset Seizures

Summary: this long-term extension study will assess the safety, tolerability and efficacy of bgg492 as adjunctive treatment in patients with partial onset seizures.


Eligibility criteria:
inclusion criteria: * completed study cbgg492a2207, cooperated with the study procedures and did not experience persistent tolerability issues * outpatients ≥ 45 kg (99 lb) of weight * patient would like to continue bgg492 treatment and the investigator believes a reasonable benefit from the long-term administration of bgg492 may be expected * treated with a stable dose of one or a maximum of three licensed antiepileptic drugs (aeds)and are known to take their medication(s) as directed * will make themselves available for the study period and are able to record seizures and report adverse events themselves or have a caregiver who can record and report the events * provided written informed consent before any extension assessment is performed exclusion criteria: * status epilepticus or seizure clusters occurring during study cbgg492a2207 or in the period between the end of study the double blind study and the start of study cbgg492a2212 for patients experiencing a treatment gap * have been treated with: * felbamate, unless treatment has been continuous for ≥ 2 years * vigabatrin during the 26 weeks prior to the first dose of open-label medication in the extension study * monoamine oxidase (mao) inhibitors, tricyclic-antidepressants and narcotic analgesics * l-dopa formulations * use of concomitant medication that are potential inhibitors of organic anion-transporting polypeptide (oatp) transporters * no physical examination changes suggestive of progressive neurological changes during study cbgg492a2207 * used another investigational drug (other than bgg492) either at the time of enrollment in this extension study or within 5 half-lives prior to enrollment in this extension study * history of hypersensitivity to the study drug or to drugs of similar chemical classes (e.g. sulfonamides) or had multiple drug allergies or one or more severe drug reactions to an antiepileptic drugs (aeds), including dermatological reactions * pregnant or nursing (lactating) women other protocol-defined inclusion/exclusion criteria may apply

Keywords: partial onset seizure seizure frequency nervous system diseases central nervous system diseases cns brain diseases neurologic manifestations adjunctive treatment aeds antiepileptic drug
rivaroxaban for the prevention of deep vein thrombosis in patients with left iliac vein compression - the plicts study

Conditions: May-Thurner Syndrome

Summary: the purpose of this study is to evaluate the efficacy and safety of rivaroxaban for the prevention of deep vein thrombosis in patients with left iliac vein compression treated with stent implantation.

left iliac vein compression syndrome (livcs) is a disease of iliac vein stenosis/occlusion caused by chronic friction and compression of the left iliac vein by the right common iliac artery and lumbar vertebra. it is also called cockett syndrome or may-thurner syndrome. recently, left iliac vein balloon dilatation with stent implantation have been used to treat patients with livcs, and have achieved good results. however, no matter the iliac vein stenosis or occlusion, interventional therapy can directly cause local trauma and intimal injury, which is a clear inducement of local thrombosis. therefore, high intensity anticoagulation therapy is still needed to prevent secondary thrombosis in stent after left iliac vein balloon dilatation with stent implantation. at present, the postoperative anticoagulation regimen of these patients is early heparin anticoagulant therapy, and later warfarin anticoagulant therapy. however, due to the narrow therapeutic window of the drug, patients need to adjust the dosage according to coagulation function under the guidance of doctors. rivaroxaban can simplify treatment, and is safe. previous studies have shown that rivaroxaban is effective in preventing deep venous thrombosis after orthopaedic surgery. rivaroxaban has also been shown to be safe and effective in anticoagulation therapy for patients with deep venous thrombosis and pulmonary embolism. however, rivaroxaban lacks sufficient clinical data for adjuvant anticoagulation therapy after balloon dilatation with stent implantation. therefore, this study should be carried out to provide the basis for livcs treatment guidelines and explore the clinical indications of rivaroxaban.

Eligibility criteria:
inclusion criteria: * patients with thrombotic left iliac vein compression syndrome who underwent left iliac vein stent implantation exclusion criteria: * age \ 75 years * with history of pelvic surgery, left iliac vein trauma and pelvic radiotherapy * with obvious contraindications for anticoagulation therapy * allergic to iodine contrast agents in the past * with concomitant diseases that need high-intensity anticoagulation, and the anticoagulation intensity is clearly higher than that of the patients with iliac vein therapy alone * active bleeding or potential bleeding risk * pregnant or breastfeeding women * with pelvic tumors causing compression of left iliac vein, * with chronic venous insufficiency of lower extremities caused by k-t syndrome * with malignant tumors and life expectancy \< 1 year * taking cytochrome p450 3a4(cyp-450 3a4) inhibitors or inducers

Keywords: may-thurner syndrome warfarin rivaroxaban stent implantation
effect of remote ischemic preconditioning on cognitive function after cardiac surgery

Conditions: Cardiac Surgery

Summary: the purpose of this study is to evaluate the effects of remote ischemic preconditioning on cognitive function in patients undergoing cardiac surgery compared to control intervention.


Eligibility criteria:
inclusion criteria: * patient undergoing heart surgery on cardiopulmonary bypass exclusion criteria: * emergency cases * myocardial infarction up to 7 days prior to enrollment * stroke up to 2 months prior to enrollment * ejection fraction less than 30% * previous psychiatric and neurological illness * inability to give informed consent

Keywords: ischemic preconditioning cognitive function
study of ag-013736 (axitinib) in patients with advanced solid tumors

Conditions: Carcinoma

Summary: to evaluate the clinically recommended dose of ag-013736 (axitinib) in japanese patients by reviewing the safety of ag-013736 (axitinib) following single and multiple dosing.


Eligibility criteria:
inclusion criteria: * patients histologically or cytologically diagnosed with advanced malignant solid tumors * patients for whom standard therapies have not been effective, or for whom there are no suitable therapies exclusion criteria: * central lung lesions involving major blood vessels * patients who have been treated with bevacizumab or other vegfr inhibitor(s)

Keywords: safety pk biomarker
a single-center, randomized, double-masked, placebo and active controlled, dose-ranging evaluation of the duration of action of brimonidine tartrate ophthalmic solution in the control of ocular redness induced by conjunctival allergen challenge (cac)

Conditions: Allergic Conjunctivitis

Summary: the purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival allergen challenge (cac) model. it is hypothesized that low-dose brimonidine tartrate ophthalmic solution will be more effective than vehicle in the prevention of conjunctival redness induced by conjunctival allergen challenge when instilled prior to the allergen challenge.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age; * if female, cannot be not pregnant or nursing * have a positive skin test reaction to cat hair, cat dander, grasses, ragweed, dog dander, cockroach, dust mite, and/or trees within the past 24 months; * have a calculated best corrected visual acuity of 0.6 logmar or better in each eye as measured using an etdrs chart; exclusion criteria: * have known contraindications or sensitivities to the use of any of the study medications(s) or their components; * have any ocular condition that, in the opinion of the investigator, could affect the subject's safety; * have a presence of active ocular infection; * use specified disallowed medications during the study or appropriate pre-study washout period; * have any significant illness; * have planned surgery (ocular or systemic) during the trial period or within 30 days after; * have used an investigational drug or device within 30 days of the study or be concurrently enrolled in another investigational drug or device study within 30 days of the study; * be a female who is currently pregnant or nursing.